Please assess the completion status of the following clinical trial:

Trial Title: Influenza Challenge Study of VIS410 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects of age 18-45 years, inclusive, at the time of informed consent.~2. Women should fulfill one of the following criteria:~   * Post-menopausal; either amenorrhea ≥ 12 months or follicle stimulating hormone \> 40 mIU/mL.~  * Surgically sterile; bilateral oophorectomy, hysterectomy, or tubal ligation.~  * Women of childbearing potential participating in heterosexual sexual relations must be willing to use adequate contraception until the end of the study.~  * Must be sexually inactive by abstinence which is consistent with the preferred and usual lifestyle of the subject.~3. Women of childbearing potential must have a negative pregnancy test at screening (serum) and on Day -2 (urine).~4. Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects must use an effective birth control method (see Inclusion Criterion 2).~5. Seronegative for the challenge virus (HAI ≤ 10).~Exclusion Criteria:~1. Known or suspected intolerance or hypersensitivity to the investigational study drug or virus.~2. Has an acute or chronic medical condition that would render the investigational study drug unsafe or would interfere with the evaluation of the responses.~3. Subjects receiving medications that affect the immune system.~4. Significant adulthood history of seasonal hay fever or a seasonal allergic rhinitis or perennial allergic rhinitis or chronic or nasal or sinus condition.~5. Subjects who have received any vaccination within the last 3 months or influenza vaccine within the last 6 months.~6. Subjects with a confirmed diagnosis of influenza A within the last 6 months prior to screening.~7. Subjects with abnormal nasal structure (including septal deviation and nasal polyps), chronic sinusitis, or reason (i.e., intolerance) that complicates nasopharyngeal swabbing.~8. Presence of lung disease, asthma, or chronic obstructive pulmonary disease.~9. Has a history of alcohol or drug abuse.~10. A positive HIV antibody screen, HBsAg, HBcAb or hepatitis C antibody screen.~11. Cancer or treatment for cancer, within 3 years, excluding basal cell carcinoma of the skin, which is allowed.~12. Presence of immunosuppression or any medical condition that may be associated with impaired immune responsiveness.~13. Anticipated presence of a household contact with potential immunosuppression.~14. History of Guillain-Barré syndrome.~15. Current professional activity as a healthcare worker who will return to work within 2 weeks following challenge.~16. Anticipated presence of a pregnant household contact, within 2 weeks following challenge.~17. Women who are pregnant or breast-feeding, or consider becoming pregnant.~18. Acute disease within 2 weeks prior to challenge.~19. Elevated white blood cell count above 10.90 x 109/L or an absolute neutrophil count above 7.5 x 109/L.~20. Current enrollment in any other investigational drug study or disease study or participation in an investigational drug study.~21. Any other reasons for which the investigator considers the subject unfit for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- VIS410 (Type: EXPERIMENTAL): Single intravenous fixed dose of VIS410
- Placebo (Type: PLACEBO_COMPARATOR): Single intravenous infusion of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete